Appello Pharmaceuticals is developing novel therapeutics for central nervous system disorders by translating recent advancements in neurobiology into drug candidates. The company aims to address the growing global burden of neurological diseases through targeted pharmacological interventions.
Funding
$32.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The global incidence and mortality rates of neurological disorders have been increasing, while pharmaceutical innovation in this area has lagged behind the growing disease burden. This gap highlights the urgent need for new therapeutic approaches to address central nervous system (CNS) disorders.
Solution
Appello Pharmaceuticals is focused on developing innovative therapeutics for CNS disorders by leveraging recent breakthroughs in neurobiology to create novel drug candidates. The company aims to translate cutting-edge research into pharmacological interventions that can effectively treat a range of neurological diseases. By focusing on targeted therapies, Appello seeks to improve the lives of patients suffering from these conditions and contribute to a paradigm shift in neurological disease treatment.
Target Audience
The primary target audience includes patients suffering from neurological disorders and the healthcare professionals who treat them.
Features
- Focus on translating recent advancements in neurobiology into drug candidates.
- Development of targeted pharmacological interventions for CNS disorders.